Inicio>>Signaling Pathways>> Proteases>> Isocitrate Dehydrogenase (IDH)>>IDH889

IDH889

Catalog No.GC38640

IDH889 es un inhibidor de isocitrato deshidrogenasa 1 (IDH1) disponible por vÍa oral, penetrante en el cerebro, alostérico y mutante especÍfico. IDH889 tiene una selectividad potente para mutaciones IDH1 R132*, con IC50 de 0,02 μM, 0,072 μM y 1,38 μM para IDH1R132H, IDH1R132C e IDH1wt, respectivamente. IDH889 muestra una potente inhibiciÓn celular de la producciÓn de R-2-hidroxiglutarato (2-HG) con una IC50 de 0,014 μM.

Products are for research use only. Not for human use. We do not sell to patients.

IDH889 Chemical Structure

Cas No.: 1429179-07-6

Tamaño Precio Disponibilidad Cantidad
1mg
102,00 $
Disponible
5mg
306,00 $
Disponible
10mg
510,00 $
Disponible
25mg
867,00 $
Disponible
50mg
1.224,00 $
Disponible
100mg
1.835,00 $
Disponible

Tel:(909) 407-4943 Email: sales@glpbio.com


Reseñas de cliente

Based on customer reviews.

  • GlpBio Citations

    GlpBio Citations
  • Bioactive Compounds Premium Provider

    Bioactive Compounds Premium Provider

Sample solution is provided at 25 µL, 10mM.

Description Chemical Properties Product Documents Related Products

IDH889 is an orally available, brain penetrant, allosteric and mutant specific inhibitor of isocitrate dehydrogenase 1 (IDH1). IDH889 has potent selectivity for IDH1 R132* mutations, with IC50s of 0.02 μM, 0.072 μM and 1.38 μM for IDH1R132H, IDH1R132C and IDH1wt, respectively. IDH889 shows potent cellular inhibition of R-2-hydroxyglutarate (2-HG) production with an IC50 of 0.014 μM[1].

[1]. Levell JR, et al. Optimization of 3-Pyrimidin-4-yl-oxazolidin-2-ones as Allosteric and Mutant Specific Inhibitors of IDH1. ACS Med Chem Lett. 2016 Dec 16;8(2):151-156.

Reseñas

Review for IDH889

Average Rating: 5 ★★★★★ (Based on Reviews and 8 reference(s) in Google Scholar.)

5 Star
100%
4 Star
0%
3 Star
0%
2 Star
0%
1 Star
0%
Review for IDH889

GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.

Required fields are marked with *

You may receive emails regarding this submission. Any emails will include the ability to opt-out of future communications.